nach oben

Erschienen in:

21.10.2021 | Review

Polymyositis and dermatomyositis: ocular manifestations and potential sight-threatening complications

verfasst von: Raul E. Ruiz-Lozano, Fabiola Velazquez-Valenzuela, Mariana Roman-Zamudio, Salma K. Andrade-Leal, Alejandro Rodriguez-Garcia

Erschienen in: Rheumatology International | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies characterized by progressive, symmetric, mainly proximal muscle weakness. DM is also characterized by cutaneous involvement. However, other clinical features, systemic involvement, histopathological findings, response to treatment, and prognosis, differ significantly. Although uncommon, ocular manifestations in DM and PM may potentially affect any structure within the eye. Notwithstanding being generally mild, ocular involvement in DM and PM may result in significant morbidity. Left untreated, significant retinal inflammation associated with hemorrhage and detachment may occur, leading to significant vision loss. This review aims to present an up-to-date overview for rheumatologists about the ocular involvement and potential complications of DM and PM and when to refer to the ophthalmologist to avoid sight-threatening complications.

Vencovsky J, Alexanderson H, Lundberg IE (2019) Idiopathic inflammatory myopathies. Rheum Dis Clin N Am 45:569–581. https://doi.org/10.1016/j.rdc.2019.07.006CrossRef

Findlay AR, Goyal NA, Mozaffar T (2015) An overview of polymyositis and dermatomyositis. Muscle Nerve 51:638–656. https://doi.org/10.1002/mus.24566CrossRefPubMed

Bruce GM (1938) Retinitis in dermatomyositis. Trans Am Ophthalmol Soc 36:282–297PubMedPubMedCentral

Hotta K (2006) Choroidopathy with serous retinal detachment in a patient with polymyositis. Eur J Ophthalmol 16:318–325. https://doi.org/10.1177/112067210601600220CrossRefPubMed

Matsuo T, Matsuura S, Nakagawa H (2000) Retinopathy in a patient with thrombotic thrombocytopenic purpura complicated by polymyositis. Jpn J Ophthalmol 44:161–164. https://doi.org/10.1016/s0021-5155(99)00187-2CrossRefPubMed

Venkatesh P, Bhaskar VM, Keshavamurthy R, Garg S (2007) Proliferative vascular retinopathy in polymyositis and dermatomyositis with scleroderma (overlap syndrome). Ocul Immunol Inflamm 15:45–49. https://doi.org/10.1080/09273940601147653CrossRefPubMed

Griger Z, Danko K, Bodoki L, Aszalos Z, Nemeth G, Ziad H, Gesztelyi R, Zsuga J, Szodoray P, Kemeny-Beke A (2020) Corneal involvement of patients with polymyositis and dermatomyositis. Ocul Immunol Inflamm 28:58–66. https://doi.org/10.1080/09273948.2018.1547407CrossRefPubMed

Backhouse O, Griffiths B, Henderson T, Emery P (1998) Ophthalmic manifestations of dermatomyositis. Ann Rheum Dis 57:447–449. https://doi.org/10.1136/ard.57.8.447CrossRefPubMedPubMedCentral

Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 373:393–394. https://doi.org/10.1056/NEJMc1506827CrossRefPubMed

10.

Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O’Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, International Myositis Classification Criteria Project consortium TEr, The Juvenile Dermatomyositis Cohort Biomarker S, Repository (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468CrossRefPubMed

11.

Rosa J, Garrot LF, Navarta DA, Saucedo C, Scolnik M, Bedran Z, Garcia MV, Sabelli M, Catoggio LJ, Soriano ER (2013) Incidence and prevalence of polymyositis and dermatomyositis in a health management organization in Buenos Aires. J Clin Rheumatol 19:303–307. https://doi.org/10.1097/RHU.0b013e3182a21ba8CrossRefPubMed

12.

Essouma M, Noubiap JJ, Singwe-Ngandeu M, Hachulla E (2021) Epidemiology of idiopathic inflammatory myopathies in Africa: a contemporary systematic review. J Clin Rheumatol. https://doi.org/10.1097/RHU.0000000000001736CrossRef

13.

Yang SH, Chang C, Lian ZX (2019) Polymyositis and dermatomyositis—challenges in diagnosis and management. J Transl Autoimmun 2:100018. https://doi.org/10.1016/j.jtauto.2019.100018CrossRefPubMedPubMedCentral

14.

Bowles NE, Dubowitz V, Sewry CA, Archard LC (1987) Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet 1:1004–1007. https://doi.org/10.1016/s0140-6736(87)92271-9CrossRefPubMed

15.

Boehler JF, Horn A, Novak JS, Li N, Ghimbovschi S, Lundberg IE, Alexanderson H, Alemo Munters L, Jaiswal JK, Nagaraju K (2019) Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis. J Pathol 249:215–226. https://doi.org/10.1002/path.5309CrossRefPubMedPubMedCentral

16.

De Paepe B, Creus KK, De Bleecker JL (2009) Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 21:610–616. https://doi.org/10.1097/BOR.0b013e3283317b31CrossRefPubMed

17.

Ellingson TL, Wilske K, Aboulafia DM (1992) Case report: thrombotic thrombocytopenic purpura in a patient with polymyositis: therapeutic importance of early recognition and discussion of pathogenic mechanisms. Am J Med Sci 303:407–410. https://doi.org/10.1097/00000441-199206000-00012CrossRefPubMed

18.

Makino H, Nagake Y, Moriwaki K, Hirakawa S, Katayama T, Yanai H, Takahashi K, Akagi T, Ota Z (1995) Thrombotic thrombocytopenic purpura and myoglobinuric acute renal failure following radiation therapy in a patient with polymyositis and cervical cancer. Intern Med 34:24–27. https://doi.org/10.2169/internalmedicine.34.24CrossRefPubMed

19.

Yamada S, Yamashita H, Nakano M, Hatano H, Sasaki T, Takahashi Y, Kaneko H (2018) Thrombotic microangiopathy with polymyositis/dermatomyositis: three case reports and a literature review. Intern Med 57:2259–2265. https://doi.org/10.2169/internalmedicine.0512-17CrossRefPubMedPubMedCentral

20.

Griger Z, Danko K, Nemeth G, Hassan Z, Aszalos Z, Szabo K, Bodoki L, Gesztelyi R, Zsuga J, Szodoray P, Kemeny-Beke A (2020) Anterior segment parameters associated with extramuscular manifestations in polymyositis and dermatomyositis. Int J Ophthalmol 13:1443–1450. https://doi.org/10.18240/ijo.2020.09.17CrossRefPubMedPubMedCentral

21.

Ruiz-Lozano RE, Hernandez-Camarena JC, Loya-Garcia D, Merayo-Lloves J, Rodriguez-Garcia A (2020) The molecular basis of neurotrophic keratopathy: diagnostic and therapeutic implications. A review. Ocul Surf 19:224–240. https://doi.org/10.1016/j.jtos.2020.09.007CrossRefPubMed

22.

Kattah JC, Zimmerman LE, Kolsky MP, Chrousos G, Chavis R, Jaffe G, Manz HJ (1990) Bilateral orbital involvement in fatal giant cell polymyositis. Ophthalmology 97:520–525. https://doi.org/10.1016/s0161-6420(90)32554-xCrossRefPubMed

23.

Isak V, Jorizzo JL (2018) Recent developments on treatment strategies and the prognosis of dermatomyositis: a review. J Dermatol Treat 29:450–459. https://doi.org/10.1080/09546634.2017.1403549CrossRef

24.

Strowd LC, Jorizzo JL (2013) Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J Dermatol Treat 24:418–421. https://doi.org/10.3109/09546634.2012.697540CrossRef

25.

Aussy A, Boyer O, Cordel N (2017) Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front Immunol 8:992. https://doi.org/10.3389/fimmu.2017.00992CrossRefPubMedPubMedCentral

26.

Furst DE, Amato AA, Iorga SR, Gajria K, Fernandes AW (2012) Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 45:676–683. https://doi.org/10.1002/mus.23302CrossRefPubMed

27.

Yang Z, Lin F, Qin B, Liang Y, Zhong R (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42:282–291. https://doi.org/10.3899/jrheum.140566CrossRefPubMed

28.

Turk MA, Hayworth JL, Nevskaya T, Pope JE (2021) Ocular manifestations in rheumatoid arthritis, connective tissue disease, and vasculitis: a systematic review and metaanalysis. J Rheumatol 48:25–34. https://doi.org/10.3899/jrheum.190768CrossRefPubMed

29.

DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82:267–281. https://doi.org/10.1016/j.jaad.2019.06.1309CrossRefPubMed

30.

Santoro FA, Huang J (2016) Ocular involvement in cutaneous connective tissue disease. Clin Dermatol 34:138–145. https://doi.org/10.1016/j.clindermatol.2015.11.011CrossRefPubMed

31.

Marasini B, Cossutta R, Massarotti M (2005) Bilateral ocular myositis as a late complication of dermatomyositis. J Rheumatol 32:2498–2499PubMed

32.

Kokotis P, Theodossiadis P, Bouros C, Sfikakis PP (2005) Bilateral ocular myositis as a late complication of dermatomyositis. J Rheumatol 32:379–381PubMed

33.

Kono S, Bunai T, Terada T, Shimoyama K, Konishi T, Shirakawa K, Miyajima H (2012) Subacute progressive ophthalmoplegia associated with dermatomyositis. J Neurol 259:1982–1984. https://doi.org/10.1007/s00415-012-6496-4CrossRefPubMed

34.

Susac JO, Garcia-Mullin R, Glaser JS (1973) Ophthalmoplegia in dermatomyositis. Neurology 23:305–310. https://doi.org/10.1212/wnl.23.3.305CrossRefPubMed

35.

Roesler J, Jenkins D Jr (2021) Lagophthalmos as a presenting sign in dermatomyositis with muscle involvement limited to the ocular muscles. JAAD Case Rep 10:44–46. https://doi.org/10.1016/j.jdcr.2021.01.035CrossRefPubMedPubMedCentral

36.

Schuster AK, Pfeiffer N, Nickels S, Schulz A, Hohn R, Wild PS, Binder H, Munzel T, Beutel ME, Vossmerbaeumer U (2016) Distribution of anterior chamber angle width and correlation with age, refraction, and anterior chamber depth-the Gutenberg health study. Invest Ophthalmol Vis Sci 57:3740–3746. https://doi.org/10.1167/iovs.16-19600CrossRefPubMed

37.

Mencucci R, De Vitto C, Cennamo M, Vignapiano R, Buzzi M, Favuzza E (2020) Femtosecond laser-assisted cataract surgery in eyes with shallow anterior chamber depth: comparison with conventional phacoemulsification. J Cataract Refract Surg 46:1604–1610. https://doi.org/10.1097/j.jcrs.0000000000000341CrossRefPubMed

38.

Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, Cameron B, Spiegel L, Schneider R, Laxer RM, Silverman ED, Feldman BM (2005) The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52:3570–3578. https://doi.org/10.1002/art.21378CrossRefPubMed

39.

Cohen S, Kremer I (1991) Bilateral corneal immune ring opacity in Behcet’s syndrome. Arch Ophthalmol 109:324–325. https://doi.org/10.1001/archopht.1991.01080030026023CrossRefPubMed

40.

Cohen BH, Sedwick LA, Burde RM (1985) Retinopathy of dermatomyositis. J Clin Neuroophthalmol 5:177–179PubMed

41.

Foroozan R (2004) Visual loss from optic neuropathy in dermatomyositis. Rheumatology (Oxford) 43:391–393. https://doi.org/10.1093/rheumatology/keh040CrossRef

42.

Yeo LM, Swaby DS, Situnayake RD, Murray PI (1995) Irreversible visual loss in dermatomyositis. Br J Rheumatol 34:1179–1181. https://doi.org/10.1093/rheumatology/34.12.1179CrossRefPubMed

43.

Liu ZH, Wang XD (2007) Acute-onset adult dermatomyositis presenting with erythroderma and diplopia. Clin Exp Dermatol 32:751–752. https://doi.org/10.1111/j.1365-2230.2007.02447.xCrossRefPubMed

44.

Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson A, Tong L, Villani E, Yoon KC, Jones L, Craig JP (2017) TFOS DEWS II diagnostic methodology report. Ocul Surf 15:539–574. https://doi.org/10.1016/j.jtos.2017.05.001CrossRefPubMed

45.

Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, Hamann S, Larkin G, McNamara NA, Greenspan JS, Daniels TE, Sjogren’s International Collaborative Clinical Alliance Research G (2010) A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren’s Syndrome International Registry. Am J Ophthalmol 149:405–415. https://doi.org/10.1016/j.ajo.2009.09.013CrossRefPubMed

46.

Ruiz-Lozano RE, Hernandez-Camarena JC, Roman-Zamudio M, Alcazar-Felix RJ, Davila-Cavazos O, Cardenas-de la Garza JA (2021) Three types of cataract associated with atopic dermatitis and chronic topical corticosteroid use: a case report. Dermatol Ther 34:e14600. https://doi.org/10.1111/dth.14600CrossRefPubMed

47.

Ruiz-Lozano RE, Hernandez-Camarena JC, Garza-Garza LA, Bustamante-Arias A, Colorado-Zavala MF, Cardenas-de la Garza JA (2020) Isotretinoin and the eye: a review for the dermatologist. Dermatol Ther 33:e14029. https://doi.org/10.1111/dth.14029CrossRefPubMed

48.

Wang Y, Morgan ML, Espino Barros Palau A, Lee AG, Foroozan R (2015) Dermatomyositis-related nonischemic central retinal vein occlusion. J Neuroophthalmol 35:289–292. https://doi.org/10.1097/WNO.0000000000000235CrossRefPubMed

49.

Migliaresi S, Ambrosone L, Tirri G (1996) Eye involvement in dermatomyositis/polymyositis. J Rheumatol 23:2006–2007PubMed

50.

Sharma M, Prashar A, Tuli R, Sharma RK, Mahajan VK (2019) Atypical central retinal artery occlusion: an uncommon cause of retinopathy and visual loss in dermatomyositis. Int J Rheum Dis 22:325–330. https://doi.org/10.1111/1756-185X.12750CrossRefPubMed

51.

Tripathy K, Salini B (2021) Amsler grid. StatPearls, Treasure Island

52.

Vezzola D, Allegrini D, Romano MR, Pagano L, Montericcio A, Fogagnolo P, Rossetti LM, De Cilla S (2019) Optical coherence tomography angiography in Purtscher-like retinopathy associated with dermatomyositis: a case report. J Med Case Rep 13:206. https://doi.org/10.1186/s13256-019-2152-2CrossRefPubMedPubMedCentral

53.

Yu H, Ma X, Tong N, Zhou Z, Zhang Y (2021) Acute exudative paraneoplastic polymorphous vitelliform maculopathy in a patient with thymoma, myasthenia gravis, and polymyositis. Eur J Ophthalmol 23:1120672121994042. https://doi.org/10.1177/1120672121994042CrossRef

54.

Ichhpujani P, Thakur S, Spaeth GL (2020) Contrast sensitivity and glaucoma. J Glaucoma 29:71–75. https://doi.org/10.1097/IJG.0000000000001379CrossRefPubMed

55.

Richman J, Zangalli C, Lu L, Wizov SS, Spaeth E, Spaeth GL (2015) The Spaeth/Richman contrast sensitivity test (SPARCS): design, reproducibility and ability to identify patients with glaucoma. Br J Ophthalmol 99:16–20. https://doi.org/10.1136/bjophthalmol-2014-305223CrossRefPubMed

56.

Rao A, Pal A, Mohapatra S (2020) Spaeth/Richman contrast sensitivity in staging glaucoma. Transl Vis Sci Technol 9:39. https://doi.org/10.1167/tvst.9.13.39CrossRefPubMedPubMedCentral

57.

Mastaglia FL, Zilko PJ (2003) Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci 10:99–101. https://doi.org/10.1016/s0967-5868(02)00271-0CrossRefPubMed

58.

van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, Uijtendaal EV, de Visser M, Dexa Myositis T (2010) Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 20:382–389. https://doi.org/10.1016/j.nmd.2010.03.011CrossRefPubMed

59.

Ernste FC, Reed AM (2013) Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 88:83–105. https://doi.org/10.1016/j.mayocp.2012.10.017CrossRefPubMed

60.

Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 92:365–369. https://doi.org/10.7326/0003-4819-92-3-365CrossRefPubMed

61.

Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24:45–48. https://doi.org/10.1002/art.1780240107CrossRefPubMed

62.

Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM (1974) Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 81:182–189. https://doi.org/10.7326/0003-4819-81-2-182CrossRefPubMed

63.

Edge JC, Outland JD, Dempsey JR, Callen JP (2006) Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142:65–69. https://doi.org/10.1001/archderm.142.1.65CrossRefPubMed

64.

Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000. https://doi.org/10.1056/NEJM199312303292704CrossRefPubMed

65.

Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51:S2-8. https://doi.org/10.1212/wnl.51.6_suppl_5.s2CrossRefPubMed

66.

Dalakas MC (2008) B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 4:557–567. https://doi.org/10.1038/ncpneuro0901CrossRefPubMed

67.

Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601–607. https://doi.org/10.1002/art.20849CrossRefPubMed

68.

Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D, Saez Moreno JA, Ortego Centeno N (2009) Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 27:1009–1016PubMed

69.

Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67:1670–1677. https://doi.org/10.1136/ard.2007.077974CrossRefPubMed

70.

Xiao Q, Hu Y, Chen F, Chen X (2008) A comparative assessment of the efficacy of carbomer gel and carboxymethyl cellulose containing artificial tears in dry eyes. J Huazhong Univ Sci Technol Med Sci 28:592–595. https://doi.org/10.1007/s11596-008-0523-9CrossRef

71.

Ang BCH, Sng JJ, Wang PXH, Htoon HM, Tong LHT (2017) Sodium hyaluronate in the treatment of dry eye syndrome: a systematic review and meta-analysis. Sci Rep 7:9013. https://doi.org/10.1038/s41598-017-08534-5CrossRefPubMedPubMedCentral

72.

Alasil T, Waheed NK (2014) Pan retinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser. Curr Opin Ophthalmol 25:164–170. https://doi.org/10.1097/ICU.0000000000000048CrossRefPubMed

73.

Kozak I, Luttrull JK (2015) Modern retinal laser therapy. Saudi J Ophthalmol 29:137–146. https://doi.org/10.1016/j.sjopt.2014.09.001CrossRefPubMed

74.

Reddy SV, Husain D (2018) Panretinal photocoagulation: a review of complications. Semin Ophthalmol 33:83–88. https://doi.org/10.1080/08820538.2017.1353820CrossRefPubMed

75.

Klettner A, Roider J (2008) Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49:4523–4527. https://doi.org/10.1167/iovs.08-2055CrossRefPubMed

76.

Daniel BS, Orchard D (2015) Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. Australas J Dermatol 56:164–169. https://doi.org/10.1111/ajd.12292CrossRefPubMed

Titel: Polymyositis and dermatomyositis: ocular manifestations and potential sight-threatening complications
verfasst von: Raul E. Ruiz-Lozano
Fabiola Velazquez-Valenzuela
Mariana Roman-Zamudio
Salma K. Andrade-Leal
Alejandro Rodriguez-Garcia
Publikationsdatum: 21.10.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 7/2022
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-05035-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Polymyositis and dermatomyositis: ocular manifestations and potential sight-threatening complications

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2022

IgG4-related disease in pediatric patients: a single-center experience

Associations between cardiac and pulmonary involvement in patients with juvenile dermatomyositis—a cross-sectional study

Toll-like receptor-7 activation in CD8+ T cells modulates inflammatory mediators in patients with rheumatoid arthritis

Pericarditis as a manifestation of IgG4-related disease

Probiotic use in the prophylaxis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: a retrospective cohort study

Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin